# Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma

> **NCT07536789** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 40 (estimated)

## Conditions studied

- Hepato Cellular Carcinoma (HCC)

## Interventions

- **DRUG:** MRG003

## Key facts

- **NCT ID:** NCT07536789
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-17
- **Primary completion:** 2028-04-15
- **Final completion:** 2029-04-14
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07536789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07536789, "Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07536789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*